ArticleItalian journal of pediatrics2024

Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered.

Francesca Nicolardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.